ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



Ò½ÏßÒ©ÎÅ1. 9ÔÂ15ÈÕ£¬£¬£¬£¬£¬£¬Ò©¼à¾Ö¹ÙÍøÏÔʾ£¬£¬£¬£¬£¬£¬Õý´óÌìÇç×¢ÉäÓô×ËáµØ¼ÓÈð¿Ë»ñÅúÉÏÊУ¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁÆÇ°ÏßÏÙ°©¡£¡£¡££¬£¬£¬£¬£¬£¬ÕâÊǺ£ÄÚÊ׿îÉÏÊеĵؼÓÈð¿Ë·ÂÖÆÒ©¡£¡£¡£µØ¼ÓÈð¿ËÊÇÒ»¿îÑ¡ÔñÐԵĴÙÐÔÏÙ¼¤ËØÊͷż¤ËØÊÜÌå (GnRHR) Þ׿¹¼ÁÀàÒ©Îï¡£¡£¡£
2. 9ÔÂ16ÈÕ£¬£¬£¬£¬£¬£¬²©ÈðÉúÎïÒ½Ò©£¨ËÕÖÝ£©¹É·ÝÓÐÏÞ¹«Ë¾Ðû²¼È«×Ê×Ó¹«Ë¾²©ÈðÖÆÒ©£¨ËÕÖÝ£©ÓÐÏÞ¹«Ë¾ÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÇ©·¢µÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬£¬£¬£¬£¬£¬Ô޳ɲ©ÈðÖÆÒ©BGM0504ƬÔÚ³ÉÈ˳¬ÖØ/·ÊÅÖ»¼ÕßÖпªÕ¹ÁÙ´²ÊÔÑé¡£¡£¡£BGM0504ÊÇÆäÑз¢µÄGLP-1ºÍGIPÊÜÌåË«ÖØ¼¤¶¯¼Á¡£¡£¡£
3. 9ÔÂ15ÈÕ£¬£¬£¬£¬£¬£¬µ¤ÂóÖÆÒ©¾ÞͷŵºÍŵµÂÐû²¼£¬£¬£¬£¬£¬£¬¿Ú·þ°æË¾ÃÀ¸ñ³ëÄ£¨Semaglutide£©ÏÖÒÑ»ñÅ·ÖÞî¿Ïµ»ú¹¹Åú×¼£¬£¬£¬£¬£¬£¬¿ÉÓÃÓÚ½µµÍÐÄѪ¹ÜéæÃü¡¢ÐÄÔಡ±¬·¢ºÍÖзçΣº¦¡£¡£¡£
4. 9ÔÂ15ÈÕ£¬£¬£¬£¬£¬£¬¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA£©¹ÙÍøÏÔʾ£¬£¬£¬£¬£¬£¬Ãñº£ÉúÎïµÄSabinÖê¼¹Ëè»ÒÖÊÑ×Ãð»îÒßÃ磨Veroϸ°û£©»ñÅúÉÏÊÐÓÃÓÚÔ¤·À¼¹Ëè»ÒÖÊÑײ¡¶¾ËùÒýÆðµÄ¼±ÐÔѬȾ²¡¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬£¬£¬ºÏ·ÊÐÇíøÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾£¨ÐÇíøÉúÎÍê³ÉÊýÍòÍòÔªÈËÃñ±ÒµÄA2ÂÖÈÚ×Ê£¬£¬£¬£¬£¬£¬±¾ÂÖÈÚ×ÊÓÉ¿·ç´´Í¶¡¢¹ú¿Æ´´Í¶µÈÅäºÏÍê³É¡£¡£¡£±¾ÂÖÈÚ×Ê×ʽð½«ÎªÐÇíøÉúÎïµÄ²úÆ·Ñз¢ÌṩÖ÷Òª×ʽðÖ§³Ö£¬£¬£¬£¬£¬£¬ÖصãÓÃÓÚ¿ªÕ¹¹«Ë¾½¹µã²úÆ·¡ª¡ª wAMD²úÆ·XMVA09µÄ¢òÆÚÁÙ´²ÊÔÑ飬£¬£¬£¬£¬£¬ÒÔ¼°Í¬²½Íƶ¯dAMD ¹ÜÏߺÍTED¹ÜÏßµÄҩѧ¡¢ÁÙ´²Ç°Ñо¿ºÍIITÁÙ´²ÊÔÑé¡£¡£¡£
1. 9ÔÂ11ÈÕ£¬£¬£¬£¬£¬£¬¹þ·ð´óѧҽѧԺ/ÂéÊ¡×ÜÒ½ÔºµÄÑо¿Ö°Ô±ÔÚ Nature ×Ó¿¯ Nature Biomedical Engineering ÉϽÒÏþÁËÌâΪ£ºTreatment of a severe vascular disease using a bespoke CRISPR¨CCas9 base editor in mice µÄÑо¿ÂÛÎÄ¡£¡£¡£¸ÃÑо¿¿ª·¢ÁËÒ»ÖÖ¸öÐÔ»¯¶¨ÖÆµÄ CRISPR-Cas9 ¼î»ù±à¼Æ÷£¬£¬£¬£¬£¬£¬ÀÖ³ÉÖÎÁÆÁ˶àϵͳƽ»¬¼¡¹¦Ð§Õϰ×ÛºÏÕ÷£¨MSMDS£©Ð¡ÊóÄ£×Ó¡£¡£¡£¡£¡£¡£
[1]Alves, C.R.R., Das, S., Krishnan, V. et al. Treatment of a severe vascular disease using a bespoke CRISPR¨CCas9 base editor in mice. Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01499-1
Ïà¹ØÐÂÎÅ